Myleran (Busulfan)

Busulfan belongs to the alkylating agent class. It forms covalent bonds with DNA, creating cross‑links that prevent DNA replication and transcription. This DNA damage leads to cell‑cycle arrest and apoptosis, especially in rapidly dividing cancerous and hematopoietic cells, providing its antineoplastic effect.

The exact dose of Myleran is individualized by the prescribing physician. Dosing is typically based on body surface area, the specific clinical indication, and therapeutic drug monitoring results. Adjustments may be made for liver function, renal function, and potential drug interactions.

Safety data for busulfan in pregnancy and lactation are limited, and the drug is generally considered contraindicated. Women of childbearing potential should use effective contraception, and breastfeeding is not recommended while receiving Myleran. Consultation with a healthcare professional is essential.

To order Myleran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The team then provides pricing, availability, shipping details and any necessary import documentation.

Compared with cyclophosphamide, another common conditioning agent, busulfan offers a more predictable pharmacokinetic profile but carries a higher risk of hepatic veno‑occlusive disease and pulmonary toxicity. Choice of agent depends on disease characteristics, patient comorbidities, and institutional protocols.

Myleran tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and avoid exposing it to excessive heat or humidity.

Myleran is taken orally as a tablet, usually with a full glass of water. The prescribing physician will specify the dosing schedule, which may involve single or divided doses. Patients should follow the exact timing and any food‑related instructions provided by their healthcare provider.

Serious risks include pulmonary fibrosis, hepatic veno‑occlusive disease, severe bone‑marrow suppression leading to aplastic anemia, seizures, and life‑threatening infections. Patients should promptly report respiratory difficulty, unexplained jaundice, persistent fever, or any neurological symptoms to their physician.

Myleran is contraindicated in patients with known hypersensitivity to busulfan, severe hepatic impairment, pre‑existing pulmonary fibrosis, or uncontrolled infections. It should also be avoided in pregnant or breastfeeding women unless the benefits outweigh the risks, and in individuals for whom the required monitoring cannot be ensured.